Sastasundar Ventures Share News - Latest Updates, Live News & More

Latest news about Sastasundar Ventures

Health X Platform Subsidiary SHBL Board Approves Restructuring Under Regulation 30 1 day ago

Health X Platform Limited disclosed that its material subsidiary SHBL's board has granted in-principle approval for a restructuring scheme involving merger with the parent company. The restructuring, communicated under Regulation 30 compliance, is contingent on the completion of Mitsubishi Corporation's 4.68% stake sale to Envision India Fund and requires independent valuation before final implementation in the next financial year.

Sastasundar Ventures Promoter Banwari Lal Mittal Acquires Additional Shares 10 days ago

Sastasundar Ventures Reports Strong Q3FY26 Performance with 22% Revenue Growth 10 days ago

NCLT Sanctions Share Capital Reduction Scheme for Sastasundar Ventures' Step-Down Subsidiary Feb 13, 2026

Sastasundar Ventures Completes Name Change to Health X Platform Limited Feb 13, 2026

More news about Sastasundar Ventures

06Feb 26

Sastasundar Ventures Reports Turnaround with Q3FY26 Consolidated Profit of Rs 36.87 Lakhs

Sastasundar Ventures Limited reported a significant turnaround in Q3FY26 with consolidated net profit of Rs 36.87 lakhs versus a loss of Rs 3,779.18 lakhs in Q3FY25. Consolidated revenue from operations grew to Rs 34,573.70 lakhs from Rs 28,129.05 lakhs year-on-year. However, standalone operations continued to face challenges with a net loss of Rs 40.99 lakhs. The Healthcare Network segment remained the primary revenue driver with Rs 34,130.31 lakhs, while Financial Services contributed Rs 443.39 lakhs during the quarter.

29Jan 26

Sastasundar Ventures Limited Schedules Board Meeting for February 6, 2026 to Consider Q3FY26 Financial Results

Sastasundar Ventures Limited has scheduled a board meeting for February 6, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The company has notified BSE and NSE under Regulation 29 of SEBI listing regulations. Trading window restrictions will remain in effect until 48 hours after the financial results are declared to stock exchanges, continuing from the closure implemented on December 26, 2025.

13Jan 26

Sastasundar Ventures Limited Announces Postal Ballot for Name Change to Health X Platform Limited

Sastasundar Ventures Limited has issued a postal ballot notice for shareholder approval of its name change to Health X Platform Limited and amendments to main object clause. The e-voting period runs from January 15-February 13, 2026, with results by February 16, 2026. The company, operating as a Core Investment Company with healthcare-focused subsidiaries, seeks to align its name with strategic business direction and expand object clause to include healthcare, pharmaceuticals, and digital platform operations.

07Jan 26

Sastasundar Ventures Limited Approves Name Change to Health X Platform Limited and Business Expansion

Sastasundar Ventures Limited's board approved a strategic transformation on January 7, 2026, including a name change to Health X Platform Limited and significant business expansion into healthcare, pharmaceuticals, wellness, and digital platform services. The company will add two new main object clauses to its Memorandum of Association, enabling operations in healthcare services, e-commerce platforms, and related technologies. These changes require shareholder approval through postal ballot with a January 9, 2026 cut-off date and regulatory approvals from government authorities.

02Dec 25

Sastasundar Ventures Promoter Banwari Lal Mittal Increases Stake to 33.76%

Sastasundar Ventures Limited promoter Banwari Lal Mittal has further increased his shareholding to 33.76% through the acquisition of 6,835 equity shares worth ₹20.61 lakh via market purchase during December 17-29, 2025. This represents the fifth consecutive transaction period where the promoter has increased his stake, with cumulative acquisitions of 42,021 shares across five periods, raising his holding from 33.63% to 33.76%.

18Nov 25

Luv Kush Projects Boosts Stake in Sastasundar Ventures

Luv Kush Projects Limited, a promoter group entity of Sastasundar Ventures Limited, acquired 20,000 equity shares worth Rs. 8,06,748.29 through a market purchase on November 17, 2025. This transaction increased their shareholding from 11.8993% to 11.9622%. The company promptly disclosed this transaction in compliance with SEBI regulations. Another promoter, Banwari Lal Mittal, also acquired 20,000 shares on the same day, increasing his stake from 33.37% to 33.4355%. Sastasundar Ventures recently hosted an Earnings Conference Call discussing their performance for the quarter and half year ended September 30, 2025.

13Nov 25

Sastasundar Ventures Narrows Q2 Loss Despite Revenue Growth

Sastasundar Ventures Limited reported a consolidated net loss of 127.00 million rupees in Q2, an 88% reduction from the 1.09 billion rupees loss in the same period last year. Revenue increased by 9.9% to 3.00 billion rupees. The company is expanding operations beyond West Bengal, focusing on product expansion, implementing a 'Quick Health Initiative', strengthening backend infrastructure, and integrating AI across its value chain.

12Nov 25

Sastasundar Ventures' Stake in Healthbuddy Subsidiary Rises to 78.89% Post Buyback

Sastasundar Ventures Limited has increased its stake in its material subsidiary, Sastasundar Healthbuddy Limited (SHBL), from 72.14% to 78.89% following a buyback offer. SHBL bought back 20,27,534 equity shares from Mitsubishi Corporation at Rs. 493.21 per share, with a total consideration not exceeding Rs. 100 crore. SHBL, incorporated in 2011, is involved in wholesale trading of medicinal products and healthcare goods, with a turnover of Rs. 1,08,498.21 lacs in the most recent fiscal year.

19Sept 25

Sastasundar Healthbuddy Approves Rs 100 Crore Share Buyback at Rs 493.21 Per Share

Sastasundar Healthbuddy Limited (SHBL), a material subsidiary of Sastasundar Ventures, has approved a share buyback program. The company plans to repurchase 20,27,534 fully paid-up equity shares at ₹493.21 per share, totaling ₹100 crore. The buyback is subject to shareholder approval. In response, Sastasundar Ventures has closed the trading window for designated persons and their immediate relatives, in compliance with SEBI regulations.

16Aug 25

SastaSundar Ventures Reports Mixed Q1 Results: B2B Growth Offsets B2C Decline

Sastasundar Ventures Limited reported a 5.9% YoY increase in total revenue to ₹278.50 crores for Q1. The B2B segment, RetailerShakti, grew by 30.9% to ₹244.50 crores, while the B2C segment, SastaSundar, declined by 55.7% to ₹33.30 crores. Financial Services revenue surged 168.9% to ₹19.90 crores. EBITDA was -₹13.80 crores, and PAT decreased by 35.1% to ₹26.60 crores. The company maintains a strong balance sheet with ₹974.40 crores in total assets, including ₹655.00 crores in liquid assets. Working capital management improved with inventory days reducing from 40 to 36 days. However, operating cash flow was negative at -₹17.30 crores, indicating ongoing operational challenges.

12Aug 25

Sastasundar Ventures Reports Robust Q1 Profit, Driven by Strong Healthcare Network Performance

Sastasundar Ventures Limited reported a consolidated net profit of Rs. 2,659.21 crore in Q1, a significant improvement from last year's loss. Total revenue from operations stood at Rs. 298.43 crore. The Healthcare Network segment contributed Rs. 278.54 crore to revenue but reported a loss, while the Financial Services segment generated Rs. 19.89 crore in revenue with a profit. On a standalone basis, the company reported a revenue of Rs. 9.67 lakh and a reduced net loss of Rs. 10.95 lakh. The Board of Directors also reviewed and amended the company's fair disclosure practices code.

30May 25

SASTASUNDAR VENTURES Reports Decline in Q4 Profit and Revenue

SASTASUNDAR VENTURES released its Q4 consolidated financial results, showing a decline in both profit and revenue. Net profit decreased by 16.46% to ₹137.00 crore from ₹164.00 crore in the previous year. Revenue fell by 7.17% to ₹285.00 crore from ₹307.00 crore year-over-year.